IRWD
IRONWOOD PHARMACEUTICALS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.43
−3.92%Price chart
Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23
Key dataOct 23, 2026
Open$3.52
From 52W high−36.36%
Volume90637.00
Market cap$566.77M
P/E (TTM)4.3x
P/S (TTM)1.5x
Div yield—
Key dataOct 23, 2026
Open
$3.52
From 52W high
−36.36%
Volume
90637.00
Market cap
$566.77M
ValuationView details →
P/E (Fwd)
2.7x
EV/EBITDA
3.7x
P/E (TTM)
4.3x
RSI (14)
40.5
MomentumView details →
1D Return
−3.92%
YTD Return
+5.93%
SummaryUpdated Jun 1, 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a Boston-based healthcare company founded in 1998 that specializes in developing and commercializing treatments for gastrointestinal disorders. Originally incorporated as Microbia, Inc., the company changed its name to Ironwood Pharmaceuticals in 2008 and went public in 2010. The company has evolved from a research-focused biotechnology firm into a commercial-stage pharmaceutical company with a primary focus on gastrointestinal therapeutics, anchored by its flagship product LINZESS and a promising pipeline candidate apraglutide for rare diseases.
Similar companies
Latest newsMore news →
Ironwood Pharmaceuticals said Thomas McCourt will retire as chief executive officer and leave the board of directors, effective December 31, 2026.7d agoIronwood Pharmaceuticals appointed Tammi Gaskins as chief executive officer and elected her to its board of directors, effective January 1, 2027; her annual base salary is $775,000, with a 75% target bonus and target equity grants valued at approximately $2 million each in RSUs and PSUs.7d ago